# Dimeric PKM2 in chondrocytes impairs mitochondrial homeostasis in osteoarthritis

**Authors:** Bo Liu, Yun Liang, Chenzhong Wang, Ziyu Weng, Yi Yang, Yi Shi, Chi Zhang

PMC · DOI: 10.1038/s41419-026-08621-4 · Cell Death & Disease · 2026-03-25

## TL;DR

This study shows that increased PKM2 dimerization in cartilage worsens osteoarthritis by disrupting mitochondrial function and extracellular matrix stability.

## Contribution

The study reveals that stabilizing PKM2 tetramers or reducing PKM2 can protect cartilage by improving mitochondrial health and ECM homeostasis.

## Key findings

- PKM2 dimerization is elevated in osteoarthritic cartilage and contributes to extracellular matrix degradation.
- Stabilizing PKM2 tetramers or deleting PKM2 preserves mitochondrial function and reduces OA progression.
- MFN1 upregulation is essential for the protective effects of PKM2 deficiency or tetramer stabilization.

## Abstract

Cartilage degradation is considered a hallmark of end-stage osteoarthritis (OA), characterized by significant alterations in the extracellular matrix (ECM). This study examines the role of pyruvate kinase muscle type 2 (PKM2) dimerization in cartilage degradation and ECM homeostasis in OA. Bioinformatic analyses identified an upregulation of PKM in OA cartilage, particularly within fibrocartilage subpopulations. Elevated expression and dimerization of PKM2 were observed in both human and murine OA cartilage. Chondrocyte-specific PKM2 deficiency, along with treatment using TEPP-46, a PKM2 tetramer stabilizer, reduced OA progression and promoted cartilage matrix production in a murine OA model with destabilization of the medial meniscus (DMM). Mechanistically, PKM2 deficiency or tetramer stabilization promoted mitochondrial fusion and preserved mitochondrial function via disruption of PKM2–ERK interaction, resulting in ERK-dependent upregulation of mitofusin 1 (MFN1), but not mitofusin 2 (MFN2). Notably, AAV-mediated MFN1 knockdown abrogated the chondroprotective effects of PKM2 deficiency. These findings indicate that targeting PKM2 dimerization may represent a promising therapeutic strategy for mitigating OA.

Increased PKM2 dimerization in osteoarthritic cartilage plays a pivotal role in extracellular matrix (ECM) degradation during osteoarthritis progression. Stabilization of PKM2 tetramers by TEPP-46 or genetic deletion of PKM2 disrupts PKM2–ERK interaction, promotes upregulation of the mitochondrial fusion protein MFN1, preserves mitochondrial function, and restores ECM homeostasis.

Increased PKM2 dimerization in osteoarthritic cartilage plays a pivotal role in extracellular matrix (ECM) degradation during osteoarthritis progression. Stabilization of PKM2 tetramers by TEPP-46 or genetic deletion of PKM2 disrupts PKM2–ERK interaction, promotes upregulation of the mitochondrial fusion protein MFN1, preserves mitochondrial function, and restores ECM homeostasis.

## Linked entities

- **Genes:** PKM (pyruvate kinase M1/2) [NCBI Gene 5315], MFN1 (mitofusin 1) [NCBI Gene 55669], MFN2 (mitofusin 2) [NCBI Gene 9927]
- **Proteins:** PKM (pyruvate kinase M1/2), EPHB2 (EPH receptor B2), MFN1 (mitofusin 1), MFN2 (mitofusin 2)
- **Chemicals:** TEPP-46 (PubChem CID 44246499)
- **Diseases:** osteoarthritis (MONDO:0005178)

## Full-text entities

- **Genes:** ACAN (aggrecan) [NCBI Gene 176] {aka AGC1, AGCAN, CSPG1, CSPGCP, MSK16, SEDK}, Pink1 (PTEN induced putative kinase 1) [NCBI Gene 68943] {aka 1190006F07Rik, BRPK, mFLJ00387}, COL11A2 (collagen type XI alpha 2 chain) [NCBI Gene 1302] {aka DFNA13, DFNB53, FBCG2, HKE5, OSMEDA, OSMEDB}, PKM (pyruvate kinase M1/2) [NCBI Gene 5315] {aka CTHBP, HEL-S-30, OIP3, PK3, PKM2, TCB}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, Mfn1 (mitofusin 1) [NCBI Gene 67414] {aka 2310002F04Rik, 6330416C07Rik, D3Ertd265e, HR2, mKIAA4032}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Pvt1 (Pvt1 oncogene) [NCBI Gene 19296] {aka Ayu21-84Imeg, Gt(pU21)84Imeg, Mis-1, Mlvi-1, Pvt-1}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 26419] {aka JNK, JNK1, Prkm8, SAPK1}, Tfam (transcription factor A, mitochondrial) [NCBI Gene 21780] {aka Hmgts, mtTFA, tsHMG}, Sox9 (SRY (sex determining region Y)-box 9) [NCBI Gene 20682] {aka 2010306G03Rik, mKIAA4243, mSox9}, Fis1 (fission, mitochondrial 1) [NCBI Gene 66437] {aka 2010003O14Rik, Ttc11}, Cdkn2a (cyclin dependent kinase inhibitor 2A) [NCBI Gene 12578] {aka ARF-INK4a, Arf, INK4a-ARF, Ink4a/Arf, MTS1, Pctr1}, Pcna (proliferating cell nuclear antigen) [NCBI Gene 18538], COL2A1 (collagen type II alpha 1 chain) [NCBI Gene 1280] {aka ACG2, ANFH, ANFH1, AOM, COL11A3, EDMMD}, Notch2 (notch 2) [NCBI Gene 18129] {aka N2}, Pkm (pyruvate kinase, muscle) [NCBI Gene 18746] {aka Pk-2, Pk-3, Pk3, Pkm2}, Nrf1 (nuclear respiratory factor 1) [NCBI Gene 18181] {aka D6Ertd415e}, OPA1 (OPA1 mitochondrial dynamin like GTPase) [NCBI Gene 4976] {aka BERHS, MGM1, MTDPS14, MTDPS14A, MTDPS14B, NPG}, COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278] {aka EDSARTH2, EDSCV, OI4}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, Col2a1 (collagen, type II, alpha 1) [NCBI Gene 12824] {aka Col2, Col2a, Col2a-1, Del1, Dmm, Lpk}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, COMP (cartilage oligomeric matrix protein) [NCBI Gene 1311] {aka CTS2, EDM1, EPD1, MED, PSACH, THBS5}, PRG4 (proteoglycan 4) [NCBI Gene 10216] {aka CACP, HAPO, JCAP, MSF, SZP}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Dnm1l (dynamin 1-like) [NCBI Gene 74006] {aka 6330417M19Rik, Dlp1, Dnmlp1, Drp1, python}, Sirt3 (sirtuin 3) [NCBI Gene 64384] {aka 2310003L23Rik, Sir2l3}, FIS1 (fission, mitochondrial 1) [NCBI Gene 51024] {aka CGI-135, TTC11}, Opa1 (OPA1, mitochondrial dynamin like GTPase) [NCBI Gene 74143] {aka 1200011N24Rik, lilr3, mKIAA0567}, Mmp13 (matrix metallopeptidase 13) [NCBI Gene 17386] {aka Clg, MMP-13, Mmp1}, Acan (aggrecan) [NCBI Gene 11595] {aka Agc, Agc1, CSPCP, Cspg1, b2b183Clo, cmd}, Adamts5 (ADAM metallopeptidase with thrombospondin type 1 motif 5) [NCBI Gene 23794] {aka 9530092O11Rik, ADAM-TS5, ADAMTS1, ADAMTS11, ADMP-2, ASMP-2}, MFN2 (mitofusin 2) [NCBI Gene 9927] {aka CMT2A, CMT2A2, CMT2A2A, CMT2A2B, CPRP1, HMSN6A}, Ctnnb1 (catenin beta 1) [NCBI Gene 12387] {aka Bfc, Catnb, Mesc}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, MFN1 (mitofusin 1) [NCBI Gene 55669] {aka hfzo1, hfzo2}, Ppargc1a (peroxisome proliferative activated receptor, gamma, coactivator 1 alpha) [NCBI Gene 19017] {aka A830037N07Rik, Gm11133, PGC-1, PPARGC-1-alpha, Pgc-1alpha, Pgc1}, MFF (mitochondrial fission factor) [NCBI Gene 56947] {aka C2orf33, EMPF2, GL004}, Rspo2 (R-spondin 2) [NCBI Gene 239405] {aka 2610028F08Rik, D430027K22, ftls}, ADAMTS5 (ADAM metallopeptidase with thrombospondin type 1 motif 5) [NCBI Gene 11096] {aka ADAM-TS 11, ADAM-TS 5, ADAM-TS5, ADAMTS-11, ADAMTS-5, ADAMTS11}, Mfn2 (mitofusin 2) [NCBI Gene 170731] {aka D630023P19Rik, Fzo}, DNM1L (dynamin 1 like) [NCBI Gene 10059] {aka DLP1, DRP1, DVLP, DYMPLE, EMPF, EMPF1}, Tceal1 (transcription elongation factor A (SII)-like 1) [NCBI Gene 237052] {aka 0610011M09Rik, P21, SIIR, pp21}, Mmp3 (matrix metallopeptidase 3) [NCBI Gene 17392] {aka EMS-2, MMP-3, SL-1, SLN-1, SLN1, STR-1}, SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662] {aka CMD1, CMPD1, ENH13, SRA1, SRXX2, SRXY10}
- **Diseases:** hypersensitivity (MESH:D004342), inflammation (MESH:D007249), synovitis (MESH:D013585), synovial hyperplasia (MESH:D006965), osteophyte (MESH:D054850), subchondral bone sclerosis (MESH:D001845), hypoxic (MESH:D002534), breast carcinoma (MESH:D001943), fibrosis (MESH:D005355), tumor (MESH:D009369), joint disorder (MESH:D007592), joint pain (MESH:D018771), cartilage damage (MESH:D002357), end-stage osteoarthritis (MESH:D007676), OA (MESH:D010003), mitochondrial (MESH:D028361), pain (MESH:D010146), bone sclerosis (MESH:D001847), Charcot-Marie-Tooth disease type 2 A. (MESH:D015417), PKM2 deficiency (MESH:C564858), medial meniscus (MESH:D000070600)
- **Chemicals:** 4-OHT (MESH:C032278), glucose (MESH:D005947), phosphoenolpyruvate (MESH:D010728), antimycin A. (MESH:D000968), 4-hydroxytamoxifen (MESH:C016601), tamoxifen (MESH:D013629), ATP (MESH:D000255), pyruvate (MESH:D019289), GAGs (MESH:D006025), disuccinimidyl suberate (MESH:C019358), DMSO (MESH:D004121), TEPP-46 (MESH:C000711471), HE (MESH:D006371), ROS (MESH:D017382), FCCP (MESH:D002259), MitoTracker Green FM (MESH:C111472), oligomycin (MESH:D009840), SB203580 (MESH:C093642), rotenone (MESH:D012402), PD98059 (MESH:C093973), Shikonin (MESH:C016101), SDS (MESH:D012967), glutamine (MESH:D005973), SP600125 (MESH:C432165), fatty acid (MESH:D005227), tricarboxylic-acid (MESH:D014233), oxygen (MESH:D010100), 2'Ome (-)
- **Species:** Adeno-associated virus (species) [taxon 272636], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** R1441G, C for 2-4, serine/threonine
- **Cell lines:** TEPP-46 — Homo sapiens (Human), Type 2 diabetes mellitus, Induced pluripotent stem cell (CVCL_B5RU), RegC-2 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_A628), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), FC-2 — Mus musculus (Mouse), Hybridoma (CVCL_B6SD)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13039331/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13039331/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC13039331/full.md

---
Source: https://tomesphere.com/paper/PMC13039331